2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

CD4 and CD8 T cells

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

5

Peptides

17

Inhibitory Antibodies

3

Natural
Products

3

Isotope-Labeled Compounds

4

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9997
    Rosnilimab

    ANB030

    		 PD-1/PD-L1 Inflammation/Immunology
    Rosnilimab (ANB030) is a PD-1 agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high PD-1 expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis .
    Rosnilimab
  • HY-148808
    Zelasudil

    RXC007

    		 ROCK Cancer
    Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma .
    Zelasudil
  • HY-150741
    ODN 2216
    1 Publications Verification

    		 Toll-like Receptor (TLR) IFNAR Interleukin Related Infection Inflammation/Immunology Cancer
    ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .
    ODN 2216
  • HY-150741C
    ODN 2216 sodium
    1 Publications Verification

    		 Toll-like Receptor (TLR) Cancer
    ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 sodium interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus .
    ODN 2216 sodium
  • HY-P99159
    Ivuxolimab

    		Interleukin Related Cancer
    Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4 + and CD8 + T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc .
    Ivuxolimab
  • HY-B0426A
    Olopatadine hydrochloride

    ALO4943A; KW4679

    		 Histamine Receptor CXCR Infection Neurological Disease Metabolic Disease Inflammation/Immunology
    Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine hydrochloride
  • HY-P11303
    PADRE peptide

    		CD74 MHC Neurological Disease Cancer
    PADRE peptide is a pan-HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4 + T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7-specific CD8 + T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C). The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA. PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer .
    PADRE peptide
  • HY-P990254
    Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173)

    		CXCR Inflammation/Immunology Cancer
    Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an anti-mouse CXCR3/CD183 IgG monoclonal antibody. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) weakens the immune response by reducing the infiltration of CD4 + and CD8 + T cells. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) significantly prolongs the survival time of heart or islet transplants in mice. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) can be used for researches on immunology and cancer such as pancreatic cancer .
    Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173)
  • HY-P991336
    Ordastobart

    INBRX-106; ES-102

    		 Orexin Receptor (OX Receptor) Inflammation/Immunology Cancer
    Ordastobart (INBRX-106; ES-102) is a hexavalent OX40 agonist antibody. Ordastobart enhances OX40 receptor clustering, signaling, and downstream activation, thereby increasing the proliferation and activation of CD4 + and CD8 + T cells in vitro and in vivo. Ordastobart exhibits anti-tumor effects and improves survival in mouse models of cancer. Ordastobart is indicated for research in cancers such as fibrosarcoma and colorectal cancer .
    Ordastobart
  • HY-P99809
    Quavonlimab

    MK-1308

    		 CTLA-4 Cancer
    Quavonlimab (MK-1308) is a humanized IgG1 monoclonal antibody targeting CTLA-4. As a competitive inhibitor of CTLA-4, Quavonlimab blocks the binding of CTLA-4 to its ligands CD80 and CD86. Quavonlimab increases interferon production, expands and activates T cells, reduces tumor regulatory T cells, inhibits tumor growth, and induces the proliferation of Ki67-positive CD4 and CD8 cells. Quavonlimab can be used in studies related to solid tumors .
    Quavonlimab
  • HY-W062109
    Olopatadine

    		Histamine Receptor CXCR Inflammation/Immunology
    Olopatadine (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine
  • HY-162133
    MSA-2-Pt

    		STING Apoptosis IKK IFNAR NF-κB Cancer
    MSA-2-Pt, platinum salt-modified MSA-2 (HY-136927), is a STING agonist. MSA-2-Pt inducing cell
    death by platinum and activating the STING pathway by MSA-2. MSA-2-Pt direct activates STING pathway, induces phosphorylation of TBK1, IRF3, and NF-κB p65. MSA-2-Pt enhances tumor infiltration of CD4 + and CD8 + T cells, and induces tumor cell death and apoptosis in mouse colon carcinoma and melanoma models .
    MSA-2-Pt
  • HY-P5453
    CFP10 (71–85)

    		CD3 Others
    CFP10 (71–85) is a biological active peptide. (CFP1071–85, that elicited IFN-γ production and CTL activity by both CD4+ and CD8+ T cells from persons expressing multiple MHC class II and class I molecules)
    CFP10 (71–85)
  • HY-P990264
    Anti-Mouse CD70 Antibody (FR70)

    		Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse CD70 Antibody (FR70) is a rat-derived ant-mouse CD70 IgG2b κ type antibody inhibitor. Anti-Mouse CD70 Antibody (FR70) decreases CD4 +, CD8 + T cells and eosinophils. Anti-Mouse CD70 Antibody (FR70) shows potent anti-inflammatory and anti-immune effects on allergic lung inflammation and cardiac transplant mice models .
    Anti-Mouse CD70 Antibody (FR70)
  • HY-P990242
    Anti-Mouse Galectin-9 Antibody (RG9-1)

    		Galectin TNF Receptor IFNAR Interleukin Related Inflammation/Immunology Cancer
    Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonal antibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of IFN-γ, TNF-α, and IL-6. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4 + and CD8 + T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia .
    Anti-Mouse Galectin-9 Antibody (RG9-1)
  • HY-P990304
    Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1)

    		TNF Receptor Infection Inflammation/Immunology Cancer
    Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) is a rat-derived IgG2a κ antibody inhibitor, targeting to mouse 4-1BBL/CD137L. Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) can block 4-1BB ligand (4-1BBL) and inhibit CD4 + and CD8 + T cells. Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) can be used for the researches of cancer, infection, inflammation and immunology, such as MC38 tumor, lymphocytic choriomeningitis virus (LCMV) infection and herpetic stromal keratitis (HSK) .
    Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1)
  • HY-W062109S
    Olopatadine-d6

    		Isotope-Labeled Compounds Histamine Receptor CXCR Inflammation/Immunology
    Olopatadine-d6 is the deuterium labeled Olopatadine. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine-d6
  • HY-P991655
    AGS-009

    		IFNAR HIV Infection Inflammation/Immunology
    AGS-009 is a humanized monoclonal neutralising antibody targeting IFN-α. AGS-009 significantly reduces activated lymphocytes, such as CD4 + and CD8 + T cells as well as B cells in SIV infection rhesus macaque models. AGS-009 can be used for autoimmune diseases like systemic lupus erythematosus (SLE) and HIV infections research .
    AGS-009
  • HY-P10593
    Influenza A NP (383-391) (HLA-B27)

    		Transmembrane Glycoprotein Influenza Virus Cancer
    Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research .
    Influenza A NP (383-391) (HLA-B27)
  • HY-W060417
    iST2-1

    		Interleukin Related Inflammation/Immunology Cancer
    iST2-1 is an Stimulation-2 (ST2) inhibitor with an IC50 value of 46.65 μM, blocks interaction between ST2 and IL-33, inhibits downstream signaling. iST2-1 functions as an immunomodulator, reduces proliferation of CD4 + and CD8 + T cells, increases regulatory T cell populations, reduces IFN-γ +CD4 + T cell populations, increases Foxp3 +CD4 + regulatory T cell populations in the gastrointestinal tract. iST2-1 reduces plasma soluble ST2 and IFN-γ levels, reduces graft-versus-host disease scores, improves survival in graft-versus-host disease animal models, preserves graft-versus-tumor effect. iST2-1 can be used for the research of graft-versus-host disease .
    iST2-1
  • HY-159123
    KHK-6

    		MAP4K Cancer
    KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC50 of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ T cells, and enhances T cell-mediated killing activity of SKOV3 and A549 cells .
    KHK-6
  • HY-13644
    Gusperimus

    15-Deoxyspergualin

    		 Others Others
    Gusperimus is a fully synthetic racemate that has a novel mechanism of action by binding to the intracellular heat shock protein hsp70 and interfering with intracellular signal transduction. This mechanism of action can enhance the effect of immunosuppressive therapy. Gusperimus can inhibit the differentiation of T cells into cytotoxic T cells, reduce the expression of IL-2 receptors on CD4 and CD8 cells, and inhibit IFN-γ-induced B cell maturation. In addition, when used with cyclosporine, tacrolimus or mycophenolate mofetil, Gusperimus can enhance the immunosuppressive effect and prevent allogeneic transplant rejection.
    Gusperimus
  • HY-157793
    SMU-L11

    		Toll-like Receptor (TLR) NF-κB MAPKAPK2 (MK2) Inflammation/Immunology Cancer
    SMU-L11 is a specific TLR7 agonist (EC50=0.024 μM), which recruits MyD88 adapter protein and activates downstream NF-κB and MAPK signaling pathways. In murine models, SMU-L11 significantly enhances immune cell activation and promotes the proliferation of CD4 + T and CD8 + T cells, thereby directly killing tumor cells and inhibiting tumor growth. SMU-L11 can be used for cancer research, and also has the potential for studying immune system diseases .
    SMU-L11
  • HY-P991318
    AR20.5

    		Mucin Cancer
    AR20.5 is a human monoclonal antibody (mAb) targeting MUC1. AR20.5 increases the number of activated CD8 T cells, CD3+CD4−CD8−(DN) T cells, and mature dendritic cells in pancreatic tumor-bearing mice. AR20.5 can be used in anti-pancreatic cancer immunity research .
    AR20.5
  • HY-B0426AS
    Olopatadine-d3 hydrochloride

    		Isotope-Labeled Compounds Histamine Receptor CXCR Inflammation/Immunology Endocrinology
    Olopatadine-d3 hydrochloride (ALO4943A-d3) is the deuterium labeled Olopatadine hydrochloride. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine-d3 hydrochloride
  • HY-B0426AR
    Olopatadine hydrochloride (Standard)

    ALO4943A (Standard); KW4679 (Standard)

    		 Reference Standards Histamine Receptor CXCR Inflammation/Immunology Endocrinology
    Olopatadine (hydrochloride) (Standard) is the analytical standard of Olopatadine (hydrochloride). This product is intended for research and analytical applications. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine hydrochloride (Standard)
  • HY-174765
    Human CCL18 mRNA

    		mRNA Inflammation/Immunology
    Human CCL18 mRNA encodes the human C-C motif chemokine ligand 18 (CCL18) protein, a cytokine that displays chemotactic activity for naive T cells, CD4+ and CD8+ T cells and nonactivated lymphocytes, but not for monocytes or granulocytes. CCL18 may play a role in both humoral and cell-mediated immunity responses.
    Human CCL18 mRNA
  • HY-174754
    Human CCL28 mRNA

    		mRNA Inflammation/Immunology
    Human CCL28 mRNA encodes the human C-C motif chemokine ligand 28 (CCL28) protein, a cytokine that displays chemotactic activity for resting CD4 or CD8 T cells and eosinophils. CCL28 may play a role in the physiology of extracutaneous epithelial tissues, including diverse mucosal organs.
    Human CCL28 mRNA
  • HY-173000
    STAT3-IN-40

    		Apoptosis Ferroptosis STAT Cancer
    STAT3-IN-40 (Compound 8b) is an anti-cancer agent. STAT3-IN-40 can trigger the immune responses of CD4+ and CD8+ T lymphocytes and induce ferroptosis and apoptosis of tumor cells by inhibiting the expression and phosphorylation of STAT3. STAT3-IN-40 can be used in the research of chemoimmunotherapeutic agents for cancer .
    STAT3-IN-40
  • HY-P10826
    PD-1/PD-L1 inhibitory peptide C8

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1 inhibitory peptide C8 is inhibits PD-1/PD-L1 interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model .
    PD-1/PD-L1 inhibitory peptide C8
  • HY-P99911
    Efizonerimod alfa

    MEDI-6383

    		 Orexin Receptor (OX Receptor) Inflammation/Immunology Cancer
    Efizonerimod alfa (MEDI-6383) is a recombinant human OX40L IgG4P Fc fusion protein that assembles into a hexameric structure and exerts potent agonist activity upon binding to OX40. The activity of Efizonerimod alfa is enhanced by Fcγ receptor-mediated aggregation. Efizonerimod alfa binds to OX40 on the surface of activated T cells, induces NF-κB promoter activity in OX40-expressing T cells, and triggers the production of Th1-type cytokines, T cell proliferation, and resistance to regulatory T cell (Treg)-mediated suppression. Efizonerimod alfa enhances the cytolytic activity of tumor-reactive T cells and slows tumor growth in immunodeficient mice. Efizonerimod alfa induces the proliferation of CD4, CD8, and B cells in the peripheral blood of healthy non-human primates. Efizonerimod alfa can be used in the research of advanced solid malignancies and melanoma .
    Efizonerimod alfa
  • HY-P991307
    BND-35

    		LILRB Transmembrane Glycoprotein Cancer
    BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model .
    BND-35
  • HY-P992063
    Anti-Mouse CD8α Antibody (YTS 105.18)

    		Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse CD8α Antibody (YTS 105.18) is a non-depleting rat IgG2a monoclonal antibody. Anti-Mouse CD8α Antibody (YTS 105.18) binds to CD8α (epitope c) on mouse CD8 + T cells; when used in combination with a non-depleting anti-CD4 antibody, it does not deplete CD8 + T cells but instead promotes the induction of peripheral tolerance in this cell subset. Anti-Mouse CD8α Antibody (YTS 105.18) can be used in studies of graft rejection .
    Anti-Mouse CD8α Antibody (YTS 105.18)
  • HY-B0426AS2
    Olopatadine-d6 hydrochloride

    ALO4943A-d6 hydrochloride; KW4679-d6 hydrochloride

    		 Isotope-Labeled Compounds Histamine Receptor CXCR Inflammation/Immunology
    Olopatadine-d6 (ALO4943A-d6; KW4679-d6) hydrochloride is deuterium-labeled Olopatadine (hydrochloride) (HY-B0426A). Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
    Olopatadine-d6 hydrochloride
  • HY-P992030
    FB102

    		Transmembrane Glycoprotein Inflammation/Immunology
    FB102 is an anti-human CD122 (IL-2Rβ) monoclonal antibody with selective activity. FB102 blocks the proliferation and activation of pathogenic NK cells and specific T cell subsets induced by IL-2 and IL-15, without affecting the proliferation of regulatory T cells. FB102 inhibits IL-2/IL-15-induced activation of CD4+ and CD8+ T cells in in vitro disease models. FB102 is applicable to research related to celiac disease .
    FB102
  • HY-182802
    Ferroptosis inducer-15

    		Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS) Mitochondrial Metabolism Cancer
    Ferroptosis inducer-15 is a ferroptosis inducer. Ferroptosis inducer-15 downregulates GPX4 expression, triggers lipid peroxidation via ROS accumulation, and disrupts mitochondrial membrane potential to drive ferroptosis. Ferroptosis inducer-15 increases splenic CD4 + T cell proportion, promotes CD8 + cytotoxic T cell tumor infiltration, and activates antitumor immune responses. Ferroptosis inducer-15 exerts antiproliferative activity against colorectal cancer cells and inhibits tumor growth in xenograft mice models without significant body weight loss. Ferroptosis inducer-15 can be used for the research of cancer, such as colorectal cancer .
    Ferroptosis inducer-15
  • HY-P992434
    OSE-279

    		PD-1/PD-L1 SHP1 Interleukin Related Cancer
    OSE-279 is a high-affinity humanized monoclonal bivalent antibody targeting PD-1, the recommended isotype control is HY-P99003. OSE-279 blocks PD-1 ligand binding, inhibits PDL1-induced SHP1 phosphorylation, restores T cell activation, and promotes reactivation of primary T cell effector functions. OSE-279 binds hFcRn receptor, predicts long half-life, induces CD4 and CD8 T cell proliferation, and promotes interleukin 2 and interferon gamma secretion. OSE-279 can be used for the research of advanced malignancies, colon cancer, hepatocarcinoma, mesothelioma .
    OSE-279
  • HY-P992056
    Anti-Human/Mouse LY6E Antibody (9B12)

    		Autophagy Cancer
    Anti-Human/Mouse LY6E Antibody (9B12) is a high-affinity, multi-target antibody that binds specifically to LY6E. Anti-Human/Mouse LY6E Antibody (9B12) binds specifically to cell-surface LY6E and enters lysosomes via lipid raft-dependent endocytosis, thereby effectively inhibiting the growth of various LY6E-expressing solid tumors (such as breast cancer and lung cancer) in both in vitro and in vivo models. Anti-Human/Mouse LY6E Antibody (9B12) exerts a dual mechanism of action: on one hand, it blocks the interaction between PILRα and CD8α, specifically reduces the survival rate of peripheral CD8 + T cells and induces their activation, breaking the state of cellular quiescence; on the other hand, it recognizes and immunoprecipitates IDE under both non-denaturing and denaturing conditions, which is applicable to studies on the subcellular localization and protein interactions of IDE. The regulatory effect of Anti-Human/Mouse LY6E Antibody (9B12) on CD8 + T cells strictly depends on the presence of PILRα, and it does not affect CD4 + T cells or T cell development in the thymus, exhibiting high specificity .
    Anti-Human/Mouse LY6E Antibody (9B12)
  • HY-P11490
    DPMI-ω

    		MDM-2/p53 Inflammation/Immunology Cancer
    DPMI-ω is a dual-specificity d-peptide antagonist of oncogenic proteins MDM2 and MDMX. DPMI-ω, upon fabrication on gold nanoparticles, efficiently traverses tumor cells and kills them by reactivating the p53 signaling pathway. DPMI-ω can disrupte the p53-MDM2/MDMX complex. DPMI-ω can inhibit B16 melanoma growth and induce cells G0/G1 phase arrest. DPMI-ω can augment the efficacy of immunotherapy by expanding CD3 +/CD8 + cytotoxic T cells and suppressing CD4 +/CD25 + regulatory T cells companied with anti-PD1 antibody. DPMI-ω can be used for research of melanoma .
    DPMI-ω
  • HY-181599
    XAN-5

    		Mitochondrial Metabolism DNA/RNA Synthesis Reactive Oxygen Species (ROS) Apoptosis Autophagy Caspase Bcl-2 Family Atg8/LC3 Cancer
    XAN-5 is a mitochondrial DNA G-quadruplex (mtG4) ligand with a Kd of 3.8 μM. XAN-5 selectively binds and stabilizes mtG4 structures, disrupting mitochondrial gene transcription and DNA replication. XAN-5 triggers mitochondrial dysfunction, ROS overproduction, G0 phase arrest and caspase-dependent apoptosis. XAN-5 inhibits autophagy and induces immunogenic cell death. XAN-5 inhibits tumor growth in a mouse liver cancer model while enhancing tumor-infiltrating CD4 + and CD8 + T cells. XAN-5 targets two cancer resistance mechanisms simultaneously. XAN-5 can be used for the research of liver cancer .
    XAN-5
  • HY-182369
    VA06

    		Toll-like Receptor (TLR) TNF Receptor Interleukin Related IFNAR Drug Derivative Inflammation/Immunology
    VA06 is a derivative of QS-21 (HY-101092A) that retains potent adjuvant activity while significantly reducing toxicity. VA06 self-assembles into flexible worm-like micelles with continuously elongated nanostructures and enhanced drug-loading encapsulation capacity. VA06 induces antigen-specific antibody production, enhances the secretion of TNF-α, IFN-γ and IL-2 in CD4 + and CD8 + T cells, and promotes the expression of immune-related and antiviral-related genes in mature dendritic cells. VA06 does not require liposome formulation, which simplifies production and storage processes. VA06 can be used in the research of varicella-zoster virus infection and Mycobacterium tuberculosis infection .
    VA06
  • HY-183784
    P2X7R antagonist-1

    		P2X Receptor FAK MMP Cancer
    P2X7R antagonist-1 is an orally active P2X7 receptor antagonist with an IC50 of 3.57 μM. P2X7R antagonist-1 inhibits the proliferation, invasion and metastasis abilities of cancer cells. P2X7R antagonist-1 downregulates the expression of FAK and MMP-9. P2X7R antagonist-1 suppresses tumor growth and metastasis in a mouse breast cancer model. P2X7R antagonist-1 promotes the activation of CD4 and CD8 T cells. P2X7R antagonist-1 can be used in breast cancer-related research .
    P2X7R antagonist-1
  • HY-181673
    ICD inducer-2

    		Microtubule/Tubulin Apoptosis Bcl-2 Family Caspase PARP Cancer
    ICD inducer-2 is a immunogenic cell death inducer. ICD inducer-2 binds to the colchicine binding site on tubulin to inhibit tubulin polymerization. ICD inducer-2 exhibits broad-spectrum antiproliferative activity across multiple cancer cell lines. ICD inducer-2 inhibits cells migration, causes G2/M phase and induces apoptosis. ICD inducer-2 promotes infiltration of CD4+ and CD8+ T cells into the tumor microenvironment. ICD inducer-2 downregulates antiapoptotic protein Bcl-2, upregulates proapoptotic proteins Bax and Bim-1, and increases cleaved caspase 3, cleaved caspase 9, and cleaved PARP levels. ICD inducer-2 overcomes paclitaxel resistance in xenograft models and achieves tumor growth inhibition. ICD inducer-2 can be used for the research of cancer, such as lung carcinoma .
    ICD inducer-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: